ORIC
NASDAQ · Biotechnology
Oric Pharmaceuticals Inc
$11.77
+0.67 (+6.04%)
Financial Highlights (FY 2025)
Revenue
151.33M
Net Income
-16,895,209
Gross Margin
60.5%
Profit Margin
-11.2%
Rev Growth
+7.8%
D/E Ratio
0.36
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | -12.7% | -10.7% | -11.4% |
| Profit Margin | -11.2% | -13.0% | -12.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 151.33M | 156.80M | 123.33M |
| Gross Profit | 91.61M | 94.92M | 74.66M |
| Operating Income | -19,200,646 | -16,841,019 | -14,080,422 |
| Net Income | -16,895,209 | -20,414,835 | -15,522,009 |
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | -12.7% | -10.7% | -11.4% |
| Profit Margin | -11.2% | -13.0% | -12.6% |
| Rev Growth | +7.8% | +20.1% | +4.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 205.57M | 268.25M | 239.63M |
| Total Equity | 573.02M | 595.16M | 557.09M |
| D/E Ratio | 0.36 | 0.45 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -22,168,918 | -26,679,727 | -20,408,682 |
| Free Cash Flow | -10,591,679 | -9,966,569 | -9,555,180 |